CONGRESS|#EHA2021| @ninashah33 presented about novel immunotherapies including CAR-T, ADCs, bispecific. It was emphasized that bringing novel therapies to 1st line will bring complications. #mmsm #myeloma @UCSFMedicine pic.twitter.com/d846109i7Y
— Multiple Myeloma Hub (@MM_Hub) June 14, 2021